1887

Abstract

Summary

A total of 116 sera from healthy individuals and from patients with Burkitt’s lymphoma (BL), nasopharyngeal carcinoma (NPC) or rheumatoid arthritis (RA) were studied with respect to antibody responses to each of the seven known transformation-associated Epstein-Barr virus (EBV)-encoded antigens [latent membrane protein (LMP) and six nuclear proteins (EBNAs 1 to 6)]. The antibodies were detected using modified standard immunoblotting techniques. Antibodies to LMP were detected for the first time in sera from 6/27 (22%) healthy, EBV-immune individuals (seropositive for the viral capsid antigens). An increased incidence of anti-LMP antibodies was found in EBV-immune sera from patients with BL (17/24 positive; 71%), NPC (21/33; 64%), and RA (16/21; 76%). Antibodies to EBNA 1 were detected in all EBV-immune sera at a standard 1:20 dilution. Antibodies to the other EBNAs were detected in only a proportion of these sera (20 to 95%) at the same dilution. Only minor disease-associated differences in the incidence of these antibodies were observed, the most consistent being that RA sera had a higher incidence of antibodies to EBNAs 2 to 6 compared with healthy controls. Testing of the sera at a 1:100 dilution suggested that there were some disease-related differences in the titres of anti-EBNA antibodies. At this serum dilution, a reduced incidence of antibodies to EBNA 2 was seen in NPC (6/31) compared with RA (18/19) and healthy EBV-seropositives (16/26); antibodies to EBNA 3 were detected at an increased incidence in BL (8/15) and NPC (16/31) compared with control sera (7/26); antibodies to EBNA 4 were detected at increased incidence in BL (5/15) and RA (6/19) compared with control sera (1/26); and antibodies to EBNA 6 were detected at increased incidence in NPC (19/31) and RA (7/19) compared with control sera (3/26).

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-69-6-1217
1988-06-01
2022-08-16
Loading full text...

Full text loading...

/deliver/fulltext/jgv/69/6/JV0690061217.html?itemId=/content/journal/jgv/10.1099/0022-1317-69-6-1217&mimeType=html&fmt=ahah

References

  1. BAER R., BANKIER A. T., BIGGIN M. D., DEININGER P. L., FARRELL P. J., GIBSON T. J., HATFULL G., HUDSON G. S., SATCHWELL S. C, SEGUIN C, TUFFNELL P. S., BARRELL B. G. 1984; DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature, London 310:207–211
    [Google Scholar]
  2. BEJARANO M. T., MASUCCI M. G., SZIGETI R., KLEIN E., KLEIN G. 1987; Defective cell-mediated response to EBV-transformed B cells in a healthy individual with regular EBV antibody titers. International Journal of Cancer 40:149–156
    [Google Scholar]
  3. BERKEL A. I., HENLE G., KLEIN G., ERSOY F., SANAL O. 1979; Epstein-Barr virus-related antibody patterns in ataxia telangiectasia. Clinical and Experimental Immunology 35:196–202
    [Google Scholar]
  4. CLEARY M. L., DORFMAN R. F., SKLAR J. 1986 Failure in immunological control of the virus in infection: post-transplant lymphomas. The Epstein-Barr Virus: Recent Advances163–182 Edited by Epstein M. A., Achong B. G. London: Heinemann;
    [Google Scholar]
  5. DE THÉ G. 1985 Epstein-Barr virus and Burkitt’s lymphoma worldwide: the causal agent revisited. Burkitt’s Lymphoma: A Human Cancer Model165–176 Edited by Lenoir G. M., O’Connor G., Olweny C. L. M. Lyon: IARC Scientific Publications; 60
    [Google Scholar]
  6. DILLNER J., KALLIN B., KLEIN G., JORNVALL H., ALEXANDER H., LERNER R. A. 1985; Antibodies against synthetic peptides react with a second Epstein-Barr virus associated nuclear antigen. EMBO Journal 4:1813–1818
    [Google Scholar]
  7. DILLNER J., KALLIN B., ALEXANDER H., ERNBERG I., UNO M., ONO Y., KLEIN G., LERNER R. A. 1986; An Epstein-Barr virus (EBV)-determined nuclear antigen (EBNA-5) partly encoded by the transformation-associated Bam WYH region of EBV DNA: preferential expression in lymphoblastoid cell lines. Proceedings of the National Academy of Sciences, U.S.A 83:6641–6645
    [Google Scholar]
  8. DILLNER J., SZIGETL R., HENLE W., HENLE G., LERNER R. A., KLEIN G. 1987; Cellular and humoral immune responses to synthetic peptides deduced from the amino-acid sequences of Epstein-Barr virus-encoded proteins in EBV-transformed cells. International Journal of Cancer 40:455–460
    [Google Scholar]
  9. FINKE J., ROWE M., KALLIN B., ERNBERG I., ROSEN A., DILLNER J., KLEIN G. 1987; Monoclonal and polyclonal antibodies against Epstein-Barr virus nuclear antigen 5 (EBNA-5) detect multiple protein species in Burkitt’s lymphoma and lymphoblastoid cell lines. Journal of Virology 61:3870–3878
    [Google Scholar]
  10. FISCHER D. K., ROBERT M., SHEDD D., SUMMERS W. P., ROBINSON J. E., WOLAK J., STEPHANO J. E., MILLER G. 1984; Identification of Epstein-Barr virus nuclear antigen polypeptide in mouse and monkey cells after gene transfer with a cloned 2-9 kilobasepair subfragment of the genome. Proceedings of the National Academy of Sciences, U.S.A 81:43–47
    [Google Scholar]
  11. GASTON J. S. H., YAO Q. Y., RICKINSON A. B., EPSTEIN M. A. 1985; The abnormal response to Epstein-Barr virus in rheumatoid arthritis is correlated with disease activity and occurs in other arthropathies. Annals of the Rheumatic Diseases 45:932–936
    [Google Scholar]
  12. HENLE W., HENLE G. 1979 The virus as the etiologic agent of infectious mononucleosis. The Epstein-Barr Virus61–78 Edited by Epstein M. A., Achong B. G. Berlin: Springer-Verlag;
    [Google Scholar]
  13. HENLE W., HENLE G. 1985 Epstein-Barr virus and human malignancies. Advances in Viral Oncology 5201–238 Edited by Klein G. New York: Raven Press;
    [Google Scholar]
  14. HENLE W., HENLE G., ANDERSSON J., ERNBERG I., KLEIN G., HORWITZ C. A., MARKLUND G., RYMO L., WELLINDER C., STRAUS S. E. 1987; Antibody responses to Epstein-Barr virus-determined nuclear antigen (EBNA)-l and EBNA-2 in acute and chronic Epstein-Barr infection. Proceedings of the National Academy of Sciences, U.S.A 84:570–574
    [Google Scholar]
  15. HENNESSY K., KIEFF E. 1983; One of two Epstein-Barr virus nuclear antigens contains a glycine-alanine copolymer domain. Proceedings of the National Academy of Sciences, U.S.A 80:5665–5669
    [Google Scholar]
  16. HENNESSY K., KIEFF E. 1985; A second nuclear protein is encoded by Epstein-Barr virus in latent infection. Science 227:1238–1240
    [Google Scholar]
  17. HENNESSY K., FENNEWALD S., HUMMEL M., COLE T., KIEFF E. 1984; A membrane protein encoded by Epstein-Barr virus in latent growth-transforming infection. Proceedings of the National Academy of Sciences, U.S.A. 81:7207–7211
    [Google Scholar]
  18. HENNESSY K., FENNEWALD S., KIEFF E. 1985; A third viral nuclear protein in lymphoblasts immortalized by Epstein-Barr virus. Proceedings of the National Academy of Sciences, U.S.A 82:5944–5948
    [Google Scholar]
  19. JOAB I., ROWE D. T., BODESCOT M., NICOLAS J.-C, FARRELL P. J., PERRICAUDET M. 1987; Mapping of the gene coding for Epstein-Barr virus-determined nuclear antigen EBNA3 and its transient overexpression in a human cell line by using an adenovirus expression vector. Journal of Virology 61:3340–3344
    [Google Scholar]
  20. KALLIN B., DILLNER J., ERNBERG I., EHLIN-HENRIKSSON B., ROSEN A., HENLE W., HENLE G., KLEIN G. 1986; Four virally-determined nuclear antigens are expressed in Epstein-Barr virus-transformed cells. Proceedings of the National Academy of Sciences, U.S.A 86:1499–1503
    [Google Scholar]
  21. KING W., THOMAS-POWELL A., RAAB-TRAUB N., HAWKE M., KIEFF E. 1980; Epstein-Barr virus RNA. V. Viral RNA in a restringently infected, growth-transformed cell line. Journal of Virology 36:506–518
    [Google Scholar]
  22. LAEMMLI U. K. 1970; Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, London 227:680–685
    [Google Scholar]
  23. MANN K. P., STAUNTON D., THORLEY-LAWSON D. A. 1985; Epstein-Barr virus-encoded membrane protein found in the plasma membranes of transformed cells. Journal of Virology 55:710–720
    [Google Scholar]
  24. MASUCCI M. G., SZIGETI R. S., ERNBERG I., MASUCCI G., KLEIN G., CHESSELS J., SIEFF C, LIE S., GLOMSTEIN A., BUSINCO L., HENLE W., HENLE G., PEARSON G., SAKAMOTO K., PURTILLO D. T. 1981; Cellular immune defects to Epstein-Barr virus-determined antigens in young males. Cancer Research 41:4284–4291
    [Google Scholar]
  25. MODROW S., WOLF H. 1986; Characterization of two related Epstein-Barr virus-encoded membrane proteins that are differentially expressed in Burkitt’s lymphoma and in vitro-transformed cell lines. Proceedings of the National Academy of Sciences, U.S.A 83:5703–5707
    [Google Scholar]
  26. MOSS D. I., CHAN S. H., BURROWS S. R., CHEW T. S., KANE R. G., STAPLES J. A., KUNARATNAM N. 1983; Epstein-Barr-virus specific T-cell response in nasopharyngeal carcinoma patients. International Journal of Cancer 32:301–305
    [Google Scholar]
  27. MUELLER-LANTZSCH N., LENOIR G. M., SAUTER M., TAKAKI K., BÉCHET J. M., KUKLIK-ROOS C, WUNDERLICH D., BORNKAMM G. 1985; Identification of the coding region for a second Epstein-Barr virus nuclear antigen (EBNA 2) by transfection of cloned DNA fragments. EMBO Journal 4:1805–1811
    [Google Scholar]
  28. POLACK A., DELLUS H., ZIMBER U., BORNKAMM G. W. 1984; Two deletions in the Epstein-Barr virus genome of the Burkitt’s lymphoma non-producer line Raji. Virology 133:146–157
    [Google Scholar]
  29. REEDMAN B. M., KLEIN G. 1973; Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines. International Journal of Cancer 11:499–520
    [Google Scholar]
  30. RICKSTEN A., KALLIN B., ALEXANDER H., DILLNER J., FÅHREUS R., KLEIN G., LERNER R., RYMO L. 1988; The BamWl E region of the Epstein-Barr virus genome encodes three transformation-associated nuclear proteins. Proceedings of the National Academy of Sciences, U.S.A 85:995–999
    [Google Scholar]
  31. ROWE D. T., FARRELL P. J., MILLER G. 1987; Novel nuclear antigens recognized by human sera in lymphocytes latently infected by Epstein-Barr virus. Virology 156:153–162
    [Google Scholar]
  32. ROWE M., GREGORY C. 1988 EBV and Burkitt’s lymphoma. Advances in Viral Oncology 8 Edited by Klein G. New York: Raven Press; in press
    [Google Scholar]
  33. ROWE M., EVANS H. S., YOUNG L. S., HENNESSY K., KIEFF E., RICKINSON A. B. 1987a; Monoclonal antibodies to the latent membrane protein of Epstein-Barr virus reveal heterogeneity of the protein and inducible expression in virus-transformed cells. Journal of General Virology 68:1575–1586
    [Google Scholar]
  34. ROWE M., ROWE D. T., GREGORY C. D., YOUNG L. S., FARRELL P. J., RUPANI H., RICKINSON A. B. 1987b; Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt’s lymphoma cells. EMBO Journal 6:2743–2751
    [Google Scholar]
  35. RYMO L., KLEIN G., RICKSTEN A. 1985; Expression of a second Epstein-Barr nuclear antigen in mouse cells after gene transfer with a cloned fragment of the viral genome. Proceedings of the National Academy of Sciences, U.S.A 82:3435–3439
    [Google Scholar]
  36. SCULLEY T. B., POPE J. H., HAZELTON R. A. 1986; Correlation between the presence of antibodies to the Epstein-Barr virus nuclear antigen type 2 and antibodies to the rheumatoid arthritis nuclear antigen in patients with rheumatoid arthritis. Arthritis and Rheumatism 29:964–970
    [Google Scholar]
  37. SEIGNEURIN J. M., LAVOUE M. F., GENOULAZ O., BORNKAMM G., LENOIR G. M. 1987; Antibody response against the Epstein-Barr virus-encoded nuclear antigen 2 (EBNA2) in different groups of individuals. International Journal of Cancer 40:349–353
    [Google Scholar]
  38. SIMIANIS V., LANE D. P. 1985; An immunoaffinity purification procedure for SV40 large T antigen. Virology 144:88–100
    [Google Scholar]
  39. SULITZEANU D., SZIGETI R., KLEIN G., HENNESSY K., KIEFF E. 1986; Leukocyte migration inhibition demonstrates a human T cell response to a membrane protein expressed in latent EBV infection. Journal of Virology 58:230–232
    [Google Scholar]
  40. SUMMERS W. P., GROGAN E. A., SHEDD D., ROBERT M., LIU C. R., MILLER G. 1982; Stable expression in mouse cells of a nuclear neoantigen after transfer of a 3-4 megadalton cloned fragment of Epstein-Barr virus DNA. Proceedings of the National Academy of Sciences, U.S.A 79:5688–5692
    [Google Scholar]
  41. SZIGETI R., SULITZEANU D., HENLE G., HENLE W., KLEIN G. 1984; Detection of an Epstein-Barr virus-associated membrane antigen in Epstein-Barr virus-transformed nonproducer cells by leukocyte migration inhibition and blocking antibody. Proceedings of the National Academy of Sciences, U.S.A 81:4178–4182
    [Google Scholar]
  42. VILMER E., LENOIR G. M., VIRELIZIER J. L., GRISCELLI C. 1984; Epstein-Barr serology in immunodeficiencies: an attempt to correlate with immune abnormalities in Wiskott-Aldrich and Chediak-Higashi syndromes and ataxia telangiectasia. Clinical and Experimental Immunology 55:249–256
    [Google Scholar]
  43. WANG F., PETTI L., BRAUN D., SEUNG S., KIEFF E. 1987; A bicistronic Epstein-Barr virus mRNA encodes two nuclear proteins in latently infected, growth-transformed lymphocytes. Journal of Virology 61:945–954
    [Google Scholar]
  44. WHITTLE H. C, BROWN I., MARSH K., GREENWOOD B. M., SEIDELIN P., TIGHE H., WEDDERBURN L. 1984; T-Cell control of Epstein-Barr virus-infected B cells is lost during P. falciparum malaria. Nature, London 312:449–450
    [Google Scholar]
  45. YOUNG L. S., DAWSON C. W., CLARK D., RUPANI H., BUSSON P., TURSZ T., JOHNSON A., RICKINSON A. B. 1988; Epstein-Barr virus gene expression in nasopharyngeal carcinoma. Journal of General Virology 69:1051–1065
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-69-6-1217
Loading
/content/journal/jgv/10.1099/0022-1317-69-6-1217
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error